Oppenheimer Cuts Capricor Therapeutics (NASDAQ:CAPR) Price Target to $22.00
Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its price target trimmed by Oppenheimer from $43.00 to $22.00 in a research note published on Monday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. A number of other research firms also recently issued reports on CAPR. Wall Street Zen downgraded Capricor Therapeutics […]
Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its price target trimmed by Oppenheimer from $43.00 to $22.00 in a research note published on Monday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. A number of other research firms also recently issued reports on CAPR. Wall Street Zen downgraded Capricor Therapeutics […]
